Navigation Links
40-year-old test procedure finds modern niche in developing new medicines
Date:1/19/2011

The blood test procedure used on newborn infants for 40 years is finding a second life in the search for new lifesaving medications, according to an article in the current edition of Chemical & Engineering News (C&EN), ACS' weekly newsmagazine.

C&EN Senior Editor Celia Henry Arnaud notes that collecting drops of blood from patients and depositing the drops on special paper cards to dry has been used for decades to screen newborns for hereditary disorders and infectious disease. But the dried blood spot technology has found a new role at pharmaceutical companies in the development and testing of new drugs.

The approach, possible now because modern lab instruments are more sensitive, has distinct advantages. The dried blood approach, for instance, involves taking only a few drops of blood from patients in clinical trials, and these can be stored and shipped more easily and inexpensively than liquid samples. Those advantages, alone, could cut the cost of introducing new drugs by millions of dollars, the article indicates.


'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
Source:Eurekalert

Page: 1

Related biology news :

1. Franklin Square to study airway bypass procedure for severe emphysema
2. Simple chemical procedure augments therapeutic potential of stem cells
3. Novel veterinary procedure detecting life-threatening injuries touted
4. Rice researchers seek better vaccine procedure
5. Growing outcomes evidence spurs renewed interest in unique heart valve procedure
6. Genetically modified cell procedure may prove useful in treating kidney failure
7. TYRX AIGISRx antibacterial envelope shows low infection rate, high CIED procedure success
8. Duke team finds compounds that prevent nerve damage
9. Study finds genetic variant plays role in cleft lip
10. In a last stronghold for endangered chimpanzees, survey finds drastic decline
11. Brown scientist finds coastal dead zones may benefit some species
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... sample of patients with undiagnosed, suspected genetic conditions, a ... a higher molecular diagnostic yield than traditional molecular diagnostic ... . The study is being released to coincide with ... Exome sequencing, which sequences the protein­coding region of the ... present in a cell or organism), has been rapidly ...
(Date:10/17/2014)... German . ... in order to reproduce? And why are there two sexes ... latest issue of the research journal Molecular Human Reproduction ... Ramm from Bielefeld University Bielefeld has compiled this special issue ... a female to copulate with several males in quick succession ...
(Date:10/17/2014)... German . ... When treating overdoses, doctors are often limited to supportive therapy ... is a combination of drugs involved. So what can be ... grandmother,s pills? ETH professor Jean-Christophe Leroux from the Institute of ... to this question. "The task was to develop an agent ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Sperm wars 2Emergency aid for overdoses 2Emergency aid for overdoses 3
... Alexandria, VA Age-related hearing loss (ARHL), one of the ... with low serum levels of folic acid, according to new ... Head and Neck Surgery . Hearing loss ... 28 million Americans between the ages of 60 and 74 ...
... that incorporates the surrounding landscape in unprecedented detail describes ... and seed dispersal in cotton plants more accurately than ... at the University of Arizona,s College of Agriculture and ... in PLoS ONE on Nov. 30. ...
... A new study published in the Journal of the ... by Autism Speaks, found that children with autism have more ... dysfunctional mitochondria. These new findings from UC Davis reveal ... way of screening for these deficits using blood samples. ...
Cached Biology News:Gene transfer from transgenic crops: A more realistic picture 2Gene transfer from transgenic crops: A more realistic picture 3Children with autism more likely to have mitochondrial defects impacting cellular energy production 2
(Date:10/20/2014)... , Oct. 20, 2014 Asterias Biotherapeutics, ... Company has signed a Notice of Grant Award ... (CIRM), effective October 1, 2014.  The NGA provides ... and the release of additional grant funds pursuant ... award for clinical development of Asterias, product, AST-OPC1. ...
(Date:10/20/2014)... Inc. (NASDAQ: GNVC ) today announced the retirement ... of directors effective on October 24, 2014.   Dr. Horovitz joined ... chairman from June 2006 to November 2013.  During his tenure, ... Audit Committees of the board.  "We deeply ... to GenVec, and its stockholders," said Wayne T. Hockmeyer ...
(Date:10/20/2014)... Earle Martin , Chief ... that Ellen Teplitzky, an experienced attorney specializing in ... industry, has joined the firm as Director of ... practice. NDA Partners provides legal services, including ... to top law firms and their clients in ...
(Date:10/19/2014)... OCTOBER 20-22, 2014: The ... ABIM will take place at the Congress ... 2014 is now available at http://www.abim.ch ... and organizations from all over the globe ... the latest products and developments on the ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Zola P. Horovitz To Retire From GenVec Board 2NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... Reportlinker.com announces that a new market research ... Global Anticoagulants Industry ... worldwide markets for Anticoagulants in US$ Million by ... Anticoagulants (Unfractionated Heparin, & Low Molecular Weight Heparin). ...
... Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so ...
... GENEVA and RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2010 ... therapeutics, today presented an update to the World Health ... antiviral compound, CMX001, at the 12th Meeting of the ... presentation titled "Status of CMX001 for Smallpox and Other ...
Cached Biology Technology:Reportlinker Adds Global Anticoagulants Industry 2Reportlinker Adds Global Anticoagulants Industry 3Reportlinker Adds Global Anticoagulants Industry 4Reportlinker Adds Global Anticoagulants Industry 5Reportlinker Adds Global Anticoagulants Industry 6Reportlinker Adds Global Anticoagulants Industry 7Reportlinker Adds Global Anticoagulants Industry 8Reportlinker Adds Global Anticoagulants Industry 9Reportlinker Adds Global Anticoagulants Industry 10Reportlinker Adds Global Anticoagulants Industry 11Reportlinker Adds Global Anticoagulants Industry 12Reportlinker Adds Global Anticoagulants Industry 13Reportlinker Adds Global Anticoagulants Industry 14Reportlinker Adds Global Anticoagulants Industry 15Reportlinker Adds Global Anticoagulants Industry 16Reportlinker Adds Global Anticoagulants Industry 17Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 2Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 3Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 4Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 5Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 6Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 7Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 8Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 9Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 10Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research 2Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research 3
Request Info...
IgD Chain C (AMS 9.1)...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Applications: Epitope mapping, Mapping protein-protein contacts, Identification of enzyme substrates/inhibitors, Identification of receptor agonists/antagonists...
Biology Products: